F-star Biotechnologische Forschungs- Und Entwicklungsges.m.b.h

S-target Therapeutics Gmbh

Baxalta Gmbh

Greenovation Biotech Gmbh

Oncoqr Ml Gmbh

Meridian Biopharmaceuticals Gmbh

Baxter International Inc.

Baxter Healthcare Sa

Dyax Corporation

Tyg Oncology Ltd.

F-star Therapeutics, Inc.

Geert Mudde

Gottfried Himmler

Gerda Redl

Anton Bauer

Maximillian Woisetschlager

Friedrich Scheiflinger

Hans Loibner

Manfred Schuster

Randolf Kerschbaumer

Florian Ruker

Gordana Wozniak-Knopp

Liesbeth Mudde-Boer

Jorge Sepulveda

Christopher Taus

Manuela Loidl

Rene Hoet

Gerhard Antoine

Dirk Voelkel

Manfred Rieger

Michael Thiele

Christof Langer

Frederick William Jacobs

Paul Christopher Broome

Juergen Muellberg

Guenter Waxenecker

Florian Rueker

Maximilian Woisetschlaeger

Florian RÜKER

Maximillian Woisetschlaeger

The invention provides for an immunogenic composition comprising a. a directed adjuvant comprising at least an anti-CD32 moiety linked to a TLR9 ligand and a first peptidic alpha-helix; and b. an immunogen comprising an extracellular Her2/neu domain that is linked to a second peptidic alpha-helix coiled to the first alpha-helix; The invention further provides a kit for producing such immunogenic composition, a vaccine comprising such immunogenic composition and its medical use, such as for treating Her2/neu positive tumor diseases.

Her2/neu immunogenic composition

A connector of a helical coiled coil-type structure connecting a first and a second molecule, wherein the first molecule comprises a peptidic first alpha-helix and the second molecule comprises a peptidic second alpha-helix, which second alpha-helix is coiled to the first alpha-helix. The first alpha-helix comprises a C-terminal region consisting of a repeat of an amino acid motif a-xand the C-terminal motif a-x-x, or an N-terminal region consisting of a repeat of an amino acid motif x-a and the N-terminal motif x-x-a, where a is a motif sequence of 4-8 amino acids, xis Lysine, and xis an extension of the motif. The extension consists of 1-10 amino acids and does not comprise more than 4 consecutive amino acids incorporated in said motif a-xor x-a. In a multimeric protein, two polypeptide chains can be connected to each other by such connector.

Coiled-coil connector

An immune-regulatory vaccine comprising&#x2014;a directed adjuvant comprising at least an anti-CD32 moiety linked to a TLR9 ligand and a first peptidic alpha-helix, and&#x2014;an immunogen with at least one epitope and a second peptidic alpha-helix coiled to the first alpha-helix, a kit for preparing the vaccine, and a sensibilizing vaccine comprising at least an anti-CD32 moiety linked to a TLR9 ligand and a peptidic alpha-helix in a pharmaceutical formulation.

Immunoregulatory vaccine

The invention provides for an immunogenic composition comprising a. a directed adjuvant comprising at least an anti-CD32 moiety linked to a TLR9 ligand and a first peptidic alpha-helix; and b. a gastrin-17 peptide immunogen linked to a second peptidic alpha-helix coiled to the first alpha-helix, which peptide immunogen is any of (i) human gastrin-17 comprising the amino acid sequence of SEQ ID 1, or a fragment thereof comprising the amino acid sequence of SEQ ID 2, or at least the 4 N-terminal amino acids of SEQ ID 2; (ii) an analog of (i), preferably of rhesus monkey or murine origin; and/or (iii) a functionally active variant of any of (i) or (ii), with one, two, three or four point mutations in the amino acid sequence of SEQ ID 2. The invention further provides a kit for producing such immunogenic composition, a vaccine comprising such immunogenic composition and its medical use, such as for treating gastrin dependent diseases.

Gastrin peptide immunogenic composition

A molecule or molecule complex capable of binding to TLR9 and to CD32 comprising at least one epitope of at least one antigen, and its use a medicament for the treatment of allergies.

Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies

The invention relates to a cytotoxic modular antibody with a molecular weight of up to 60 kD, specifically binding to a cell surface target with a binding affinity of Kd&#x3c;10M, a method of producing such antibody and its use as a therapeutic.

Cytotoxic immunoglobulin

The present application relates to a method of preparing a genetic package displaying oligomers of modular antibody domains binding to a target and to a scaffold ligand as well as to vectors and libraries of genetic packages produced thereby. The invention further relates to methods of selecting suitable linker sequences for use in such oligomer display.

Display of binding agents

The present invention is concerned with the specific and highly sensitive detection of specific CHO-MIF (macrophage migration inhibitory factor from Chinese Ovarian Hamster cell line) complexes in the production of anti-MIF antibodies. The present invention is further concerned with the provision of specific antibodies which can be used for a CHO-MIF detection method. The present invention is also concerned with a CHO MIF knockout cell line and use thereof. The present invention also provides preparations obtained from recombinant production in CHO cell lines which are essentially free of CHO-MIF.

Characterization of CHO-MIF gene and protein, and use thereof

The present invention relates to a method of preparing a genetic package displaying oligomers of modular antibody domains binding to a target and to a scaffold ligand as well as to vectors and libraries of genetic packages produced thereby. The invention further relates to methods of selecting suitable linker sequences for use in such oligomer display.

The invention relates to a cytotoxic modular antibody with a molecular weight of up to 6 OkD, specifically binding to a cell surface target with a binding affinity of Kd&#x3c;10M, a method of producing such antibody and its use as a therapeutic.

The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions.

Anti MIF antibodies

The invention relates to a monoclonal antibody or derivative or fragment thereof that is derived from a parental monoclonal antibody, that recognizes the Lewis Y antigen, characterized in that the Fc region or region equivalent to the Fc region of said antibody or derivative or fragment thereof carries a bi-sected hybrid type N-glycosylation pattern and that said antibody shows at least 10 fold increased ADCC and at least 10% reduced CDC activity.

Method of treating lewis Y-expressing tumors

The invention relates to a monoclonal antibody, or fragment of the antibody, that is derived from a parental monoclonal antibody, that recognizes the Lewis Y antigen, characterized in that the Fc region of the antibody, or fragment of the antibody, carries a bi-sected hybrid type N-glycosylation pattern and that the antibody shows at least 10 fold increased ADCC and at least 10% reduced CDC activity.

Growing community of inventors

Breitenfurt, Austria

Geert Mudde